William H Matthai

Summary

Affiliation: University of Pennsylvania
Country: USA

Publications

  1. ncbi Evaluation of thrombocytopenia in the acute coronary syndrome
    William H Matthai
    Department of Medicine, University of Pennsylvania Medical School, Philadelphia, Pennsylvania 19104, USA
    Curr Opin Hematol 17:398-404. 2010
  2. ncbi Safety and efficacy of argatroban in patients with heparin-induced thrombocytopenia
    William H Matthai
    University of Pennsylvania Medical School, Penn Presbyterian Medical Center, Philadelphia, PA 19104, USA
    Curr Hematol Rep 5:95-9. 2006
  3. ncbi Treatment of heparin-induced thrombocytopenia in cardiovascular patients
    William H Matthai
    Penn Presbyterian Medical Center, WS 392, Philadelphia, PA 19104, USA
    Expert Opin Pharmacother 7:267-76. 2006
  4. ncbi Thrombocytopenia in cardiovascular patients: diagnosis and management
    William H Matthai
    University of Pennsylvania Medical Center Presbyterian, 39th and Market St, Philadelphia, PA 19104, USA
    Chest 127:46S-52S. 2005
  5. ncbi Argatroban anticoagulation in patients with a history of heparin-induced thrombocytopenia
    William H Matthai
    University of Pennsylvania Medical School, 39th and Market Sts WS 392, Philadelphia, PA 10104, USA
    Thromb Res 116:121-6. 2005
  6. ncbi Evaluating the etiology of mechanical valve obstruction: use of clinical parameters, fluoroscopy, and echocardiography
    Anthony Licata
    Division of Cardiovascular Medicine, University of Pennsylvania Medical School, Philadelphia, Pennsylvania 19104, USA
    Catheter Cardiovasc Interv 55:495-500. 2002
  7. ncbi Effective management of acute coronary thrombosis in a young woman with lupus using aggressive medical therapy
    Parin J Patel
    Hospital of the University of Pennsylvania, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
    Cardiology 118:45-9. 2011
  8. ncbi One-year clinical outcomes of protected and unprotected left main coronary artery stenting
    Michael P Kelley
    Hospital of the University of Pennsylvania, University Health System, 9 Gates, 3400 Spruce Street, Philadelphia, PA 19104, USA
    Eur Heart J 24:1554-9. 2003
  9. ncbi Argatroban anticoagulation during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia
    Bruce E Lewis
    Loyola University Medical Center, Maywood, Illinois, USA
    Catheter Cardiovasc Interv 57:177-84. 2002
  10. ncbi Argatroban anticoagulation in conjunction with glycoprotein IIb/IIIa inhibition in patients undergoing percutaneous coronary intervention: an open-label, nonrandomized pilot study
    Ik Kyung Jang
    Cardiology Division, Gray Bigelow 800, Massachusetts General Hospital and Harvard Medical School, 55 Fruit Street, Boston, MA 02114, USA
    J Thromb Thrombolysis 18:31-7. 2004

Collaborators

Detail Information

Publications11

  1. ncbi Evaluation of thrombocytopenia in the acute coronary syndrome
    William H Matthai
    Department of Medicine, University of Pennsylvania Medical School, Philadelphia, Pennsylvania 19104, USA
    Curr Opin Hematol 17:398-404. 2010
    ..Treatment strategies, both medical and mechanical, may cause thrombocytopenia. This review will introduce a differential diagnosis, diagnostic strategies, and treatment options for patients with an acute coronary syndrome...
  2. ncbi Safety and efficacy of argatroban in patients with heparin-induced thrombocytopenia
    William H Matthai
    University of Pennsylvania Medical School, Penn Presbyterian Medical Center, Philadelphia, PA 19104, USA
    Curr Hematol Rep 5:95-9. 2006
    ..There is somewhat limited experience with its use in a number of other clinical scenarios in these patients. The current data on the use of argatroban in patients with HIT are reviewed...
  3. ncbi Treatment of heparin-induced thrombocytopenia in cardiovascular patients
    William H Matthai
    Penn Presbyterian Medical Center, WS 392, Philadelphia, PA 19104, USA
    Expert Opin Pharmacother 7:267-76. 2006
    ..These agents and their use in cardiac patients, including patients with acute coronary syndrome, percutaneous coronary interventions, acute ST elevation myocardial infarction or cardiac surgery, will be reviewed...
  4. ncbi Thrombocytopenia in cardiovascular patients: diagnosis and management
    William H Matthai
    University of Pennsylvania Medical Center Presbyterian, 39th and Market St, Philadelphia, PA 19104, USA
    Chest 127:46S-52S. 2005
    ..The use of a direct thrombin inhibitor in treatment should be considered early if a diagnosis of heparin-induced thrombocytopenia is possible...
  5. ncbi Argatroban anticoagulation in patients with a history of heparin-induced thrombocytopenia
    William H Matthai
    University of Pennsylvania Medical School, 39th and Market Sts WS 392, Philadelphia, PA 10104, USA
    Thromb Res 116:121-6. 2005
    ..We evaluated the safety and efficacy of argatroban, a direct thrombin inhibitor, as an anticoagulant in patients with a history of HIT needing acute anticoagulation...
  6. ncbi Evaluating the etiology of mechanical valve obstruction: use of clinical parameters, fluoroscopy, and echocardiography
    Anthony Licata
    Division of Cardiovascular Medicine, University of Pennsylvania Medical School, Philadelphia, Pennsylvania 19104, USA
    Catheter Cardiovasc Interv 55:495-500. 2002
    ..Clinical evaluation and diagnostic evaluation with fluoroscopy and echocardiography in distinguishing pannus from thrombus are reviewed...
  7. ncbi Effective management of acute coronary thrombosis in a young woman with lupus using aggressive medical therapy
    Parin J Patel
    Hospital of the University of Pennsylvania, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
    Cardiology 118:45-9. 2011
    ..Assessing clinical risk factors and using technologies such as intravascular ultrasound can help make the correct treatment decision...
  8. ncbi One-year clinical outcomes of protected and unprotected left main coronary artery stenting
    Michael P Kelley
    Hospital of the University of Pennsylvania, University Health System, 9 Gates, 3400 Spruce Street, Philadelphia, PA 19104, USA
    Eur Heart J 24:1554-9. 2003
    ..Stenting for unprotected LMCA disease in a high-risk population should only be considered in the absence of other revascularization options. Further studies are needed to evaluate the role of stenting for unprotected LMCA disease...
  9. ncbi Argatroban anticoagulation during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia
    Bruce E Lewis
    Loyola University Medical Center, Maywood, Illinois, USA
    Catheter Cardiovasc Interv 57:177-84. 2002
    ..Overall, outcomes were comparable with those historically reported for heparin. Argatroban therefore is a reasonable anticoagulant option in this setting, where current options are limited...
  10. ncbi Argatroban anticoagulation in conjunction with glycoprotein IIb/IIIa inhibition in patients undergoing percutaneous coronary intervention: an open-label, nonrandomized pilot study
    Ik Kyung Jang
    Cardiology Division, Gray Bigelow 800, Massachusetts General Hospital and Harvard Medical School, 55 Fruit Street, Boston, MA 02114, USA
    J Thromb Thrombolysis 18:31-7. 2004
    ..This multicenter, prospective pilot study evaluated the efficacy and safety of argatroban in combination with glycoprotein IIb/IIIa inhibition in patients undergoing percutaneous coronary intervention...
  11. ncbi Role of cardiac troponin T in the long-term risk stratification of patients undergoing percutaneous coronary intervention
    Jorge R Kizer
    Division of Cardiology, Department of Medicine and Public Health, Weill Medical College of Cornell University, New York, NY, USA
    Eur Heart J 24:1314-22. 2003
    ..Whether the prognostic significance of smaller post-procedural TnT elevations extends beyond the intermediate-term awaits further investigation...